Works matching AU Sawalha, Y.

Results: 7
    1

    Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 597, doi. 10.1002/hon.3164_447
    By:
    • Bond, D. A.;
    • Wei, L.;
    • Yildiz, V.;
    • Reneau, J.;
    • Sawalha, Y.;
    • Christian, B.;
    • Brammer, J.;
    • Epperla, N.;
    • Koff, J.;
    • Dendorfer, A.;
    • Yang, L.;
    • Baiocchi, R.;
    • Voorhees, T.;
    • Sigmund, A. M.;
    • Hanel, W.;
    • Shindiapina, P.;
    • Denlinger, N.;
    • Penza, S.;
    • Jaglowski, S.;
    • Bezerra, E.
    Publication type:
    Article
    2
    3

    OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 156, doi. 10.1002/hon.3163_103
    By:
    • Messmer, M.;
    • Stack, A.;
    • Deng, M.;
    • Handorf, E.;
    • Kapoor, N.;
    • Sawalha, Y.;
    • Bock, A. M.;
    • Wang, Y.;
    • Graf, K.;
    • Greenwell, B.;
    • Cleveland, J.;
    • Advani, R.;
    • Herrera, D. Adrianzen;
    • Cai, E.;
    • Spinner, M.;
    • Hassan, A.;
    • Rajguru, S.;
    • Phillips, M. S.;
    • Smith, S. D.;
    • Brooks, T.
    Publication type:
    Article
    4
    5

    MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 405, doi. 10.1002/hon.75_2631
    By:
    • Hill, B.T.;
    • Switchenko, J.M.;
    • Martin, P.;
    • Churnetski, M.C.;
    • Sawalha, Y.;
    • Goyal, S.;
    • Shanmugasundaram, K.;
    • Calzada, O.;
    • Kolla, B.;
    • Bachanova, V.;
    • Gerson, J.N.;
    • Barta, S.K.;
    • Maldonado, E.;
    • Gordon, M.;
    • Danilov, A.;
    • Grover, N.S.;
    • Mathews, S.;
    • Burkart, M.;
    • Karmali, R.;
    • Ghosh, N.
    Publication type:
    Article
    6

    MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 405, doi. 10.1002/hon.75_2631
    By:
    • Hill, B.T.;
    • Switchenko, J.M.;
    • Martin, P.;
    • Churnetski, M.C.;
    • Sawalha, Y.;
    • Goyal, S.;
    • Shanmugasundaram, K.;
    • Calzada, O.;
    • Kolla, B.;
    • Bachanova, V.;
    • Gerson, J.N.;
    • Barta, S.K.;
    • Maldonado, E.;
    • Gordon, M.;
    • Danilov, A.;
    • Grover, N.S.;
    • Mathews, S.;
    • Burkart, M.;
    • Karmali, R.;
    • Ghosh, N.
    Publication type:
    Article
    7

    Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis.

    Published in:
    Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01271-3
    By:
    • Sawalha, Y.;
    • Sarosiek, S.;
    • Welkie, R. L.;
    • Seif, S.;
    • Thapa, S.;
    • Zanwar, S.;
    • Cahill, K.;
    • Treitman, R.;
    • Shah, H.;
    • Arora, S.;
    • Pongas, G.;
    • Winter, A.;
    • Major, A.;
    • Riedell, P. A.;
    • Palomba, M. L.;
    • Kapoor, P.;
    • Grajales-Cruz, A.;
    • Shain, K. H.;
    • Thomas, S. K.;
    • Castillo, J. J.
    Publication type:
    Article